2025 年 4 月 11 日，复旦大学附属中山医院葛均波院士、戴宇翔主任医师、林金钟教授和龚惠教授合作在Circulation 杂志在线发表题为「Modified mRNA Treatment Restores Cardiac Function ...

值得一提的是，这一研究也为心肌病的治疗提供了新的视角和框架，强调了从基因、蛋白质水平的功能恢复对疾病治愈的重要性。随着技术的不断进步和发展，我们期待这种创新的mRNA治疗能早日应用于临床，帮助更多患者重获健康。 返回搜狐，查看更多 ...

Tenaya Therapeutics (TNYA) announced interim data from its ongoing RIDGE natural history and seroprevalence study of adults with arrhythmogenic ...

Arrhythmogenic right ventricular dysplasia, or ARVD — also known as arrhythmogenic right ventricular cardiomyopathy, or ARVC — is a genetic condition (autosomal dominant) affecting the ...

Abbreviations: ARVD/C, arrhythmogenic right ventricular dysplasia/cardiomyopathy; VT, ventricular tachycardia. Author's Contributions: P Petrakopoulou and M Greif contributed equally to the ...

Background Regular intensive physical activity is associated with non-pathological changes in cardiac morphology. Differential diagnosis with arrhythmogenic right ventricular cardiomyopathy (ARVC) ...

The first-line therapy for arrhythmogenic right ventricular cardiomyopathy (ARVC) is considered to be β-blockers, which are generally well tolerated. However, findings from the Multidisciplinary ...

A team at the Centro Nacional de Investigaciones Cardiovasculares (CNIC) has developed an innovative gene-therapy strategy that could transform the treatment of arrhythmogenic right ventricular ...

Over time, repetitive injury may lead to changes that resemble right (or less often) left ventricular (LV) cardiomyopathy, even in the absence of underlying demonstrable genetic abnormalities. The ...